Related Experiment Video
Updated: Jan 22, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Association Between Cystatin C and the Risk of Ischemic Stroke: a Systematic Review and Meta-analysis
1Xi'an Medical University, No 74 Hanguangbei Road, Xi'an, 710068, Shaanxi, China.
Insights
Elevated cystatin C levels are linked to a higher risk of ischemic stroke. This finding suggests cystatin C may serve as a valuable biomarker for predicting stroke risk, particularly in acute cases.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Biomarker Research
Background:
- Ischemic stroke significantly impacts patient health and quality of life.
- Cystatin C is emerging as a potential biomarker for cardiovascular diseases.
Purpose of the Study:
- To conduct a meta-analysis assessing the association between cystatin C and ischemic stroke risk.
- To evaluate cystatin C as a predictor for ischemic stroke, especially in acute and subclinical forms.
Main Methods:
- A systematic literature search was conducted for studies examining cystatin C and ischemic stroke.
- A random-effects meta-analysis was performed on data from nine studies.
- Included were 3773 patients with ischemic stroke and control participants.
Main Results:
- Patients with ischemic stroke exhibited significantly higher serum cystatin C concentrations (pooled mean difference: 0.11; 95% CI: 0.00–0.22; P=0.04).
- Elevated cystatin C was particularly noted in acute ischemic stroke (mean difference: 0.23; 95% CI: 0.11–0.36; P=0.0003).
- Higher cystatin C levels were also associated with subclinical cerebral infarction (mean difference: 0.07; 95% CI: 0.05–0.09; P<0.00001).
Conclusions:
- Cystatin C is significantly associated with an increased risk of ischemic stroke.
- Cystatin C demonstrates potential as a predictive biomarker for ischemic stroke.
- The predictive value of cystatin C is especially pronounced in acute ischemic stroke and subclinical cerebral infarction.
Abstract:
Ischemic stroke is a disease that affects people's health and quality of life. Cystatin C has been found as a new biomarker of cardiovascular disease. We performed this meta-analysis to assess the relationship between cystatin C and the risk of ischemic stroke. The studies on looking at the association between cystatin C and ischemic stroke were identified from inception to November 18, 2018. We performed a random-effects meta-analysis using mean difference. Nine studies with a total of 3773 ischemic stroke patients were included into the meta-analysis. Our results showed that patients with ischemic stroke had significantly higher serum cystatin C concentrations compared with the participants without ischemic stroke (pooled mean difference, 0.11; 95% confidence interval (CI), 0.00-0.22; P = 0.04), in particular acute ischemic stroke and subclinical cerebral infarction (mean difference, 0.23; 95% CI, 0.11-0.36; P = 0.0003 and mean difference, 0.07; 95% CI, 0.05-0.09; P < 0.00001, respectively). Cystatin C was associated with ischemic stroke, and it could be considered a predictor for the risk of ischemic stroke, especially in acute ischemic stroke and subclinical cerebral infarction.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups
Relative Risk
Systematic Sampling Method
Systematic sampling is one of the simplest methods...

